Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study - Gianni, L; Huang, C S; Egle, D (San Antonio Breast Cancer Symposium, 2019)
et al.